The h4 coil surface region of human papillomavirus type 58 L1 virus-like particle serves as a potential location for presenting the RG1 epitope peptide
The licensed prophylactic human papillomavirus (HPV) vaccines, based on L1 virus-like particles (VLPs), effectively prevent infection and HPV-associated cancers caused by the vaccine types but offer limited protection against non-vaccine types. L2 N-terminal peptides, such as the RG1 epitope peptide...
Saved in:
| Main Authors: | Zhirong Wang, Ting Zhang, Xuemei Xu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2025.2477966 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Integrated in-silico design and in vivo validation of multi-epitope vaccines for norovirus
by: Jingxuan Qiu, et al.
Published: (2025-05-01) -
An mRNA-based workflow validating neo-epitope presentation through HLA-I/peptide affinity purification
by: Arthur Esprit, et al.
Published: (2025-06-01) -
Designing a multi-epitope vaccine against SARS-CoV-2: an immunoinformatic approach
by: V. Alamdari-Palang, et al.
Published: (2025-07-01) -
In silico screening and identification of CTL and HTL epitopes in the secreted virulence factors of Mycobacterium tuberculosis
by: Edward Kevin Bragais, et al.
Published: (2025-03-01) -
T and B cell epitope analysis for the immunogenicity evaluation and mitigation of antibody-based therapeutics
by: Ruoxuan Sun, et al.
Published: (2024-12-01)